Loading...
XLONABDX
Market cap18mUSD
Dec 24, Last price  
7.75GBP
1D
0.00%
1Q
-16.67%
IPO
-92.67%
Name

Abingdon Health PLC

Chart & Performance

D1W1MN
XLON:ABDX chart
P/E
—
P/S
244.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.99%
Rev. gr., 5y
21.92%
Revenues
6m
+51.67%
2,268,4462,277,2935,235,00011,618,0002,835,0004,045,0006,135,000
Net income
-1m
L-63.17%
3,469,540-1,260,077-3,374,000-6,973,000-21,262,000-3,451,000-1,271,000
CFO
-2m
L
-2,550,270-908,2542,095,000-12,876,000-7,735,0001,002,000-1,659,000
Earnings
Mar 12, 2025

Profile

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.
URL
https://www.abingdonhealth.com/
IPO date
Dec 15, 2020
Employees
74
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑06
Income
Revenues
6,135
51.67%
4,045
42.68%
2,835
-75.60%
Cost of revenue
7,574
7,891
14,940
Unusual Expense (Income)
NOPBT
(1,439)
(3,846)
(12,105)
NOPBT Margin
Operating Taxes
(128)
(355)
(423)
Tax Rate
NOPAT
(1,311)
(3,491)
(11,682)
Net income
(1,271)
-63.17%
(3,451)
-83.77%
(21,262)
204.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,136
BB yield
-19.13%
Debt
Debt current
120
87
265
Long-term debt
1,256
932
1,015
Deferred revenue
Other long-term liabilities
88
(708)
(435)
Net debt
(77)
(2,217)
(1,117)
Cash flow
Cash from operating activities
(1,659)
1,002
(7,735)
CAPEX
(35)
(157)
(760)
Cash from investing activities
(23)
(156)
(760)
Cash from financing activities
(114)
(7)
5,915
FCF
(1,604)
1,930
(727)
Balance
Cash
1,440
3,236
2,397
Long term investments
13
Excess cash
1,146
3,034
2,255
Stockholders' equity
(28,559)
(27,300)
(23,877)
Invested Capital
31,945
31,232
30,385
ROIC
ROCE
EV
Common stock shares outstanding
304,732
304,033
291,623
Price
0.10
-14.58%
0.12
9.09%
0.11
-77.48%
Market cap
31,235
-14.39%
36,484
13.73%
32,078
-31.59%
EV
31,158
34,267
30,961
EBITDA
(1,013)
(3,173)
(10,468)
EV/EBITDA
Interest
57
72
69
Interest/NOPBT